AI Health Pioneer Qure.ai Receives Gates Foundation Support to Build Open-Source Lung Health Database

In an effort to advance health equity and reach the people that need help most, global digital health innovator Qure.ai has received a grant from the Gates Foundation.

The multimillion-dollar grant will allow Qure.ai to develop a large open-source multi-modal database to further advance future prevention and identification innovations. It will support WHO lung-health diagnostic pathways plus augment non-identifiable clinical history, medical images (Chest X-Ray, Thoracic Ultrasound, High Resolution CT), cough/lung recordings, and laboratory or biological markers to enable researchers and innovators around the world to develop, validate, and refine new AI models for the good of all.

This grant will also allow Qure.ai to develop AI-enabled point-of-care ultrasound algorithms as a ‘tool’ for the early detection of TB and pneumonia, two of the world’s deadliest infectious diseases in under-resourced regions. Both are curable if caught early yet TB deaths are approximately 1.23 million annually, pneumonia 2 million each year, 700,000 of which are children under five.

Prashant Warier, Founder and CEO of Qure.ai

In a bid to reach the unreachable we have innovated our way around the world over the last 10 years, taking AI-enabled X-ray to some of the remotest regions of sub-Saharan Africa, to the heights of Everest and depths of rural Southeast Asia, tackling the detection and diagnosis of TB. This is powerful progress that has reduced diagnosis rates from 14 days to 1-2 days, without even a clinician present. Now, with this grant from the Gates Foundation, we are excited to leverage this expertise further to scale and reach more people,” states Prashant Warier, Founder and CEO of Qure.ai.

“With the very latest developments in digital health and artificial intelligence, Qure.ai can help reach healthcare’s blind spots, bringing high-quality diagnostics within reach of every clinic, health worker, and child, no matter where they live,” adds Dr. Shibu Vijayan, Chief Medical Officer – Global Health at Qure.ai.

“This grant will allow us to build on the years of continuous innovation we have spearheaded in public health and our commitment to pushing the boundaries of what AI can do for global health. It brings together pneumonia, tuberculosis, and broader lung health priorities, with a focus on children in low and middle-income countries. A child dies of pneumonia every 43 seconds which is an unacceptable and an avoidable loss. It underscores the urgent need for better diagnostics and equitable access to care,” said Dr Justy Antony Chiramal, Project Lead and Clinical Director, Global Health Innovation at Qure.ai.

Qure.ai is a global health innovator, with deployments across 105+ countries and 4,800+ sites worldwide identifying and managing TB, Lung Cancer and Neurocritical findings such as Stroke.

About Qure.ai

Qure.ai is a global AI company innovating diagnostic solutions in healthcare for early detection and care management. Qure's solutions power early diagnosis in lung cancer, neurology and infectious disease to support clinicians and propel developments in the pharmaceutical and medical device industries. The company empowers healthcare workers or health systems by helping to identify conditions fast, prioritize treatment planning and ultimately improve quality of patient life.

Qure.ai has deployments in over 105 countries, with regional offices in New York, London, Dubai and Mumbai. It is a TIME100 Most Influential Company 2025

AI Meets Cardiology: Bayosthiti and Narayana Partner to Predict Heart Disease in Indian Patients

Bayosthiti AI, an innovator in AI-driven healthcare and molecular diagnostics, announced a strategic partnership with Narayana Health, one of the world's largest cardiac care networks, to develop AI models that predict cardiovascular disease in Indian patients. The collaboration leverages RNA sequencing to read the active molecular instructions in cells, combined with gen AI to identify heart disease risk earlier and more accurately than conventional methods.

The study will analyze transcriptomic data (the complete set of active cellular RNA messages) from over 12,000 participants at Narayana Institute of Cardiac Sciences in Bengaluru. Using Bayosthiti's proprietary BIRT™ technology, researchers will sequence complete RNA profiles from patient blood samples to train AI models. These models will be capable of detecting distinctive patterns of cellular activity that signal coronary artery disease (blockages in heart arteries) before traditional tests show abnormalities.

Coronary artery disease affects 65 million Indians and strikes at younger ages than in Western populations. Yet, diagnostic tools remain largely calibrated to European and American patient data, creating what clinicians call the "Data Gap." Standard risk scores miss critical patterns in South Asian biology shaped by distinct genetic backgrounds and environmental factors, leading to late-stage diagnoses when intervention options narrow.

Bayosthiti AI and Narayana Health are solving this through molecular innovation and clinical scale. Narayana performs over 60,000 cardiac procedures annually, generating rich clinical data. Bayosthiti's BIRT™ (Barcode-Integrated Reverse Transcription) technology sequences complete RNA profiles at a fraction of traditional costs by processing multiple patient samples in parallel. This breakthrough makes it economically viable to build the massive datasets required to train robust AI models tailored for Indian populations, ensuring highly accurate and individualized genetic analysis.

Current diagnostics rely on anatomical imaging or protein markers, both of which detect disease after it has physically manifested. RNA sequencing captures the dynamic instructions cells are executing in real time. By analyzing which genetic instructions are being transcribed (actively used to make proteins) and at what levels, Bayosthiti's AI can detect when biological systems shift toward disease states, potentially months or years before structural damage appears.

"Just as Google Translate learned language patterns from billions of text examples, our AI learns disease patterns from millions of RNA expressions," said Dr. Rishabh M. Shetty, Head of Business Development and Clinical Applications at Bayosthiti AI. "The transcriptome gives us a real-time readout of what the body is doing right now. Our models can spot the molecular conversation that precedes a heart attack, not just the aftermath, and can do so with the same level of accuracy and efficacy as invasive procedures or other current imaging gold standards."

The clinical credibility matters. Narayana Health's scale and reputation make it an ideal validation partner. Its leadership views AI integration as the next frontier in expanding access and improving outcomes. "AI-based technologies aren't the future of medicine. They're the present," said Dr. P.M. Uthappa, Group Chief Medical Director at Narayana Health. "This collaboration lets us move from intervention to prevention. The ability to identify high-risk patients earlier and more precisely is a clinical game-changer."

The partnership builds on Bayosthiti's momentum since establishing operations in India. The company has processed samples from over 100 collaborations globally, and this study represents a significant expansion in both scope and strategic importance.

"We've relied too long on a one-size-fits-all approach to medicine," said Kutapa Muthanna, CEO of Bayosthiti AI. "This isn't just about closing a data gap. It's about building the foundation for proactive, personalized medicine created by Indians, for Indians. When we can tell someone their heart disease risk is rising before any scan shows blockage, we transform care from reactive to preventive."

The three-phase study design allows for continuous improvement. Successfully validating these AI models would provide proof-of-concept for deploying similar approaches for other high-burden diseases in India. As the partnership progresses, findings will inform the development of a blood-based diagnostic test deployable at scale across India's healthcare system.

About Bayosthiti AI

Bayosthiti AI, a wholly-owned subsidiary of US-based Biostate AI, is India’s first AI-first healthcare company pioneering Lifetime Health Management. By integrating patented BIRT™ and other cutting-edge molecular technologies with advanced generative AI, Bayosthiti is building a foundational health-tech platform for India. This platform includes 24/7 AI Clinical Assistants and AI Scientists for patients, clinicians, and researchers, making personalized precision care a reality for all.

For more information, visit https://bayosthiti.ai/.

About Narayana Hrudayalaya

Narayana Hrudayalaya, operating under the brand name Narayana Health, is one of India’s leading private healthcare service providers. The group operates a nationwide network of hospitals with a mission to deliver high-quality, safe and technology-enabled healthcare to the broader population. Renowned globally for its expertise in Cardiac Sciences, Narayana Health has been at the forefront of heart care for over two decades, performing one of the highest volumes of cardiac procedures in the world.

As the only hospital group in India with Enterprise-level Joint Commission International (JCI) accreditation, Narayana Health upholds the highest standards of quality and patient safety across its network. Guided by its core values of Quality, Compassion, and Innovation, Narayana Health remains committed to its vision of ‘Health for all. All for Health.’

For more information, visit narayanahealth.org.

IIT-AIIMS Jodhpur Develop AI Tool to Revolutionize Childhood Malnutrition Screening

• The IIT-AIIMS Jodhpur team have developed DomainAdapt, an AI-powered framework to detect childhood malnutrition using photos. Coupled with the AnthroVision dataset, it provides fast, scalable & accurate assessment of stunting, wasting & underweight in children.

Researchers at the Indian Institute of Technology (IIT) and All India Institute of Medical Science (AIIMS) Jodhpur have leveraged the power of artificial intelligence (AI) to better identify malnutrition in children.

The new method, published in the open-access journal MICCAI, addresses one of the most pressing global health challenges, the accurate and scalable assessment of childhood malnutrition.

The study introduced DomainAdapt, a novel multitasking learning framework that dynamically adjusts task weights using domain knowledge and mutual information.

This allows the system to more accurately predict key anthropometric measures such as height, weight and mid-upper arm circumference (MUAC), while simultaneously classifying malnutrition-related conditions such as stunting, wasting and underweight.

While these measures are also assessed using the traditional screening methods, they pose challenges in terms of the subjectivity of the worker, the time-consuming process of measuring each aspect one by one, and the lack of scalability.

“By simply capturing photos of a child, our framework can estimate nutritional status without the need for complex and time-consuming anthropometric measurements.” explained Misaal Khan, a doctoral student in medical technology at IIT-AIIMS, who led the study.

Misaal Khan

“This makes malnutrition screening faster, more accessible and highly scalable, especially in resource-limited settings.” Khan added.

Further, a cornerstone of the research is AnthroVision, a first-of-its-kind dataset containing 16,938 multi-pose images from 2,141 children collected across both clinical (AIIMS Jodhpur) and community (government schools in Rajasthan) settings.

The dataset captures diverse backgrounds, clothing and lighting conditions, making it a robust resource for advancing automated child health assessment.

Through rigorous experimentation, DomainAdapt demonstrated significant improvements over existing multitask learning methods, offering a reliable AI-driven solution to accelerate malnutrition detection worldwide.

“This research represents a vital step toward equitable healthcare access.” said Khan.

“By blending AI and domain expertise, we can empower healthcare workers and public health systems with tools that are cost-effective, accurate, and scalable.” she added.

Life Sciences Leaders Reimagine AI-Powered Commercialization at Indegene Digital Summit 2025

Senior life sciences executives convene at the Indegene Digital Summit 2025 to explore how AI is transforming commercialization. The invite-only event at Philadelphia’s iconic Barnes Foundation features global experts sharing real-world insights and showcases programs delivering measurable impact.

Now in its 7th edition, Indegene Digital Summit is a flagship thought leadership platform for the life sciences industry, facilitating dialogue among senior executives, regulators, and digital innovators. This year’s theme, “From Chaos to Clarity - and Better Decisions”, focused on delivering tangible value beyond the hype of Generative AI (GenAI).

Industry leaders share how they are transforming commercial operations, advancing technology initiatives, and rethinking strategy to drive greater impact. Executives engage in wide-ranging yet practical discussions on data unification across the value chain, agent-augmented workforce, GenAI in commercial operations, evolving pharma regulations, zero-rep commercial models, and the future of customer engagement, among others.

The Vital Awards: Recognizing Leaders Shaping the Future of Life Sciences

At the Summit, the Vital Awards celebrates life sciences professionals at the forefront of scientific and technological convergence - who embody bold thinking, transformative work, and an unwavering pursuit of progress to define the future of healthcare. The awards honor innovation and impact across 4 categories:

1. Patient Impact: Leaders engaging, supporting, and empowering patients through innovative treatments, campaigns, or programs.
2. Community Impact: Leaders contributing knowledge, leadership, and action to benefit underserved groups, healthcare professionals, not-for-profits, academia, and the broader ecosystem.
3. Organizational Impact: Leaders transforming organizations through bold and innovative use of data, technology adoption, and fostering collaboration.
4. Market Impact: Leaders driving measurable market success through innovative launch strategies, go-to-market models, and operational excellence.

All nominations underwent a rigorous evaluation by a distinguished, cross-disciplinary jury comprising senior leaders from industry, academia, policy, media, and analyst domains of the life sciences ecosystem. The jury included:

• Chris Lee, VP-Regulatory Affairs Innovation and Strategic Operations, Gilead Sciences
• Dr. David Shulkin, Ninth Secretary, US Department of Veterans Affairs
• Jameson Fleming, Editor-in-Chief, MM+M
• Jill DeSimone, Former President-US Oncology, Merck
• Navneet Puri, Founder & Board Member, Nevakar
• Dr. Nimita Limaye, VP-Research, Life Sciences, IDC
• Dr. Rajesh Nair, President, Indegene, Inc.
• Reynold Panettieri, Vice Chancellor, Rutgers University, and,
• Tanya Monga, SVP-Global Commercial Strategy and Operations, Gilead Sciences

Their combined expertise and diverse perspectives selected honorees based on innovation, measurable impact, and leadership excellence across the life sciences ecosystem.

Vital Awards 2025 Honorees

• Patient Impact: Sunil Verma, SVP, Global Head, Oncology Franchise, AstraZeneca
• Organizational Impact: Nathan Bowmaker, Head of Global Commercial Operations, AstraZeneca; and Catherine Galvin, VP, Global Marketing Digital & AI Business Transformation, Merck
• Market Impact: Marion Dumas, Global Head of Omnichannel, Sanofi

Speaking on the occasion, Manish Gupta, Chairman and CEO, Indegene, said, “Many congratulations to all the honorees. Your innovation and impact are helping our industry shift growth trajectories and become future-ready, inspiring the broader ecosystem to redefine what’s possible. I also want to thank our eminent jury for recognizing leaders whose breakthroughs continue to push the boundaries.”

Indegene Digital Summit is a #FutureReadyHealthcare initiative, orchestrated by Indegene.

For live updates, follow #FutureReadyHealthcare on LinkedIn.

With deep conversations sans sales pitches, the summit continues to facilitate an open exchange of ideas, encourage collaboration, and promote thought leadership. For the session recordings, summaries and more, visit: https://digitalsummit.indegene.com/

AI Designs Viruses That Kill Bacteria—A New Frontier in Synthetic Biology

In a stunning leap for synthetic biology, scientists have used artificial intelligence to design viruses that can infect and kill bacteria—ushering in a new era of programmable life forms and potentially revolutionizing medicine.

Researchers at Stanford University and the Arc Institute trained an AI model named Evo on over 2 million bacteriophage genomes. The goal? To teach the system how nature builds viruses that target bacteria. Evo didn’t just remix existing genetic material—it generated 302 entirely new viral genomes, many of which had never existed in nature.

Of those, 16 assembled into fully functional viruses that successfully infected and destroyed E. coli bacteria in lab tests. This marks the first time AI has been used to design complete, working viruses from scratch.

“We’re not just accelerating evolution—we’re directing it,” said one of the lead researchers. “This opens the door to custom-built phages that could target antibiotic-resistant bacteria with surgical precision.”

Why This Matters

• Antibiotic resistance is one of the biggest threats to global health, with superbugs killing over a million people annually.
• Phage therapy, which uses viruses to kill bacteria, has long been seen as a promising alternative—but finding the right phage is slow and unpredictable.
• AI could dramatically speed up the discovery and design of targeted phages, potentially enabling personalized treatments for infections.

The Ethical Frontier

While the study focused solely on bacteriophages and excluded viruses that infect humans, the implications are profound. Experts warn that AI-designed viruses could behave unpredictably in complex ecosystems. There are also concerns about biosecurity and the potential misuse of such technology.

“We need robust oversight and ethical frameworks,” said a bioethicist not involved in the study. “This is powerful tech, and with great power comes great responsibility.”

What’s Next?

• The team plans to expand Evo’s capabilities to design phages for other bacterial strains, including those responsible for hospital-acquired infections.
• There’s growing interest in using AI to design viruses for agriculture, microbiome engineering, and environmental cleanup.

This breakthrough isn’t just about killing bacteria—it’s about reimagining what life can be. With AI as a co-creator, biology may no longer be bound by the slow march of evolution. It’s entering the age of intelligent design.

Dectrocel Bags ₹4 Crore from BioAngels, PadUp Ventures to Accelerate AI-Powered Healthcare Tools

Dectrocel, a pioneering health-tech company developing AI-powered diagnostic solutions, has raised ₹4 crore in recent funding. The round was led by IAN Group-powered BioAngels, with participation from PadUp Ventures and Vinners.

Key investors from IAN in this round include Nitin Zamre, Samir Kalia, and Mitesh Shah. The fresh infusion of capital will be used to scale Dectrocel’s commercial operations across India, enhance its self-learning foundational multimodal AI technology, expand into international markets, and accelerate the launch of its upcoming AI Tools in CT /MRI/PET-CT and HPB diagnostic modules.

Headquartered in Lucknow, Uttar Pradesh, Dectrocel has launched its flagship product, DecXpert, which is one of only three AI-based diagnostic tools approved by the Central Drugs Standard Control Organization (CDSCO) for clinical use in India. The platform delivers chest X-ray and CT-scan interpretations that are 10 times faster and 98% accurate, addressing India’s acute radiologist shortage - currently at a staggering 1:125,000 doctor-to-patient ratio. This shortage results in diagnosis delays of 7 to 10 days and error rates of up to 40%, particularly in tier-2 and smaller cities where timely intervention can be life-saving.

Dectrocel was founded by Ankit Shukla, an AI-in-medicine expert from the University of Queensland; MS in Infectious Diseases from Duke Medical School, NUS, Singapore. Saumya Shukla, a Doctorate in Public Health from SGPGIMS with an MBA from NUS and MS in Data Science from Harvard; and Nikhil Mishra, an IIT Kanpur Researcher specializing in AI and machine learning applications in medicine.

The company’s mission stems from a deeply personal experience where a patient with a persistent cough went undiagnosed for months due to delayed X-ray interpretations and ultimately succumbed to late-stage lung cancer. This tragedy transformed the founders’ vision into a life-saving mission to democratize access to expert-level diagnostic capabilities for every patient, regardless of geography or income.

UST and ThinkBio.Ai Forge Strategic Alliance to Accelerate AI-Driven Innovation in Biopharma and Healthcare

UST, a leading digital transformation solutions company, has partnered with ThinkBio.Ai®, an AI-powered solutions provider for biopharmaceutical and healthcare organizations. This strategic partnership will empower UST to more efficiently leverage its expertise in digital transformation and advanced solutions to complement ThinkBio.Ai’s innovative AI-powered R&D capabilities. Together, the companies will deliver transformative solutions that accelerate AI transformation journeys and improve outcomes for biopharma and healthcare organizations worldwide.

Leveraging advanced in-house expertise in oncology, immunology, neurology, and cardiology, ThinkBio.Ai has developed a suite of AI-powered solutions to address critical challenges across pharma and biotech preclinical and clinical R&D pipelines. These include data-driven strategies to identify the most optimal treatments, salvaging failed drugs through repurposing or combination therapies, and improving clinical trial success through biomarker-driven patient stratification and digital twin-enabled trial matching.

In addition, ThinkBio.Ai’s AI-enhanced Research Co-pilot (R-COP™) utilizes AI to extend the existing Laboratory Information Management System (LIMS) capabilities. Fully interoperable with existing infrastructure, this next-generation tool transforms routine processes into dynamic, insight-driven research operations. These solutions are designed to support biopharma companies and healthcare providers in accelerating innovation and improving patient care.

ThinkBio.Ai’s biological and clinical insights are powered by experts and delivered through the BioThinkHub™ data platform, drawing from expertly curated data and knowledge from proprietary and public data sources.

“This partnership will bring our unique AI and knowledge-based transformation products and solutions for Research and Discovery (R&D) to UST’s focus on digital transformation capabilities and building Gen AI solutions for different industries, including the life science sector. Together, we will build custom ecosystems to help clients and partners stay ahead in a well-regulated, dynamic, and competitive landscape,” said Pradeep Palazhi, Founder and Chief Executive Officer, ThinkBio.Ai®.

“We will integrate ThinkBio.Ai’s AI-powered R&D transformation solutions with UST’s strengths in digital transformation and Gen AI across life sciences – pharma, biotech, and medical devices. This strategic collaboration will drive innovation, accelerate time-to-value, and deliver measurable impact across the research and development value chain for our customers,” said Anu Koshy, Life Science cluster leader, UST.

Jaslok Hospital Partners with AnginaX AI to Launch Maharashtra’s First Operational AI-Powered Heart Disease Prevention Model

In a landmark initiative that could redefine how India tackles its leading cause of death, Jaslok Hospital & Research Centre has partnered with AnginaX AI, India’s first licensed AI Doctor Assistant in cardiology, to launch Maharashtra’s first operational AI-powered heart disease prevention model.

This collaboration places Jaslok at the forefront of India’s shift from late-stage cardiac intervention to early, technology-driven prevention. The advanced AnginaX AI system, now deployed across Jaslok’s outpatient departments, enables doctors to assess cardiovascular risk in just seconds using structured, science-backed reports that identify risk even before symptoms appear and recommend personalized lifestyle and treatment plans.

With heart disease affecting millions of Indians and often going undetected until it’s too late, this prevention model brings speed, clarity, and access to the very first point of contact: the OPD.

“For decades, cardiology has focused on damage control.” said Padma Bhushan Awardee Dr. Ashwin B. Mehta, Director of Cardiology at Jaslok Hospital. “But with advanced AI, we can now assess who is at risk before damage begins. This is not just innovation, but reimagining the timeline of care."

The AnginaX system evaluates more than 20 critical clinical and lifestyle-based indicators, including extended lipid profiles, blood sugar, inflammatory biomarkers, metabolic complexities, family history, and lifestyle patterns. Based on validated Indian data, the system generates a structured clinical summary that includes individualized risk stratification, investigation recommendations specific to each patient, and clear, actionable treatment and follow-up guidance.

“The AnginaX AI system gives us clinical clarity in under a minute, especially vital in high-volume OPD settings.” said Dr. Ajit Desai, Senior Cardiologist at Jaslok. “We’re now able to consult more patients, detect silent risks early, and guide people to act before their first symptom.”

Recognizing that cost and fear are often barriers to early checkups, Jaslok and AnginaX have ensured the program is fast, accessible and affordable, making prevention routine rather than rare.

“This isn’t just about digital transformation, but about medical timing,” said Mr. Jitendra Haryan, CEO of Jaslok Hospital. “Our hospital is proud to lead this change in India’s healthcare system. When technology and medicine work together, lives are saved earlier.”

Jaslok also launched AI-powered initiative “Dil Fit, Life Hit” under the leadership of Dr. Ashwin B. Mehta, bringing structured cardiovascular prevention into everyday clinical care. The program empowers doctors, transforms OPD practice, and makes prevention accessible to every patient, not just those with symptoms.

Naman Gosalia, Founder of AnginaX AI, added: “We’ve built an advanced AI medical system that fits seamlessly into any hospital or clinic, helping doctors halt the progression of cardiovascular disease through precision-led risk assessment and personalized treatment recommendations. Our mission is to bring primary prevention to every clinic, every hospital and every corner of India without disrupting how doctors practice.”

“The KPI of this model was simple: could it work on my own mother? We made a clear decision that we would only release it if it worked on her. We tested it on our mother first before going into the pilot. That trial was successful and it gave us the conviction to move forward.” he said.

“Launching it at Jaslok and having their leadership activate it first in Maharashtra, reflects a shared belief that people deserve better outcomes, and prevention should not come with fear, friction, or financial burden. This partnership helps us put the patient first and take this mission to scale across India.”

Dr. Neeraj Desai, Strategic Medical Advisor at AnginaX AI said, “AnginaX AI system is a bridge between data and decision, between missed chances and timely care. In medicine, timing is everything. And for the first time, we are putting timing on the side of prevention”. 

AI-based screening has already begun at Jaslok. Doctors are now taking swift, informed preventive steps, especially for patients who might otherwise remain undiagn

AI-Powered Eye Scan Slashes Diagnosis Time from Weeks to Seconds!

Taiwan-based Acer Medical’s artificial intelligence-assisted diagnostic software and a combination of Intel hardware- and software-based technology, is making eye lesion detection dramatically faster, said Acer Medical, a subsidiary of Acer group in an official blog post.

Traditionally, diagnosing conditions like diabetic retinopathy or age-related macular degeneration could take weeks, especially when multiple specialists were involved. Now, thanks to Acer Medical’s AI-assisted diagnostic software running on Intel-backed AI PCs, results can be delivered in seconds.

The system uses high-resolution fundus photography to scan the inner eye, with AI algorithms analyzing images instantly. This eliminates the need for dilation-related eye drops and long wait times. The AI PC processes everything locally, meaning no internet connection is required—making it ideal for remote healthcare.

 

Dr. Hsieh Yi-Ting (foreground) demonstrates detailed eye scans of a patient on his Acer Travelmate Spin P4 AI PC, connected to a high-resolution fundus camera. Thanks to AI algorithms developed using Intel OpenVINO tool kits, the medical team sees results in just 10 seconds. (Image Credit: Intel Corporation)

Results are processed using Acer Medical’s VeriSee DR for diabetic retinopathy and VeriSee Age-related Macular Degeneration (VeriSee AMD) for age-related macular degeneration.

Created by Acer Medical in partnership with medical specialists, the technology is available in 13 countries.

Dr. Hsieh Yi-Ting, a retina specialist at National Taiwan University Hospital, developed the VeriSee DR and VeriSee AMD solutions, which are now available in 13 countries. These tools help doctors prioritize cases and expedite treatment, but they don’t replace medical professionals—rather, they enhance their ability to provide faster, more accurate care.

Acer Medical is a subsidiary of the Acer Group specializing in AI-driven medical diagnostics. They focus on leveraging artificial intelligence, clinical data, and software development to create healthcare solutions. The company's technology has been implemented in over 300 hospitals and clinics, serving an estimated 450,000 patients annually.

Their AI-powered tools, like VeriSee DR and VeriSee AMD, help detect eye diseases such as diabetic retinopathy and age-related macular degeneration in seconds, significantly reducing diagnosis time.

 
This AI-driven approach is a game-changer for rural healthcare, allowing specialists to diagnose patients far from hospitals. What do you think about AI’s expanding role in medicine? Do comment your opinion below...

66% HealthTech Leaders Say Their Organizations Generating Business Value From Several Ai Use Cases :KPMG Report

KPMG has unveiled a new report titled “KPMG Global Tech Report: Healthcare Insights” to better understand how healthcare organizations are navigating the complexities of digital transformation, targeting their technology investments, and deriving value.

By examining the perspectives of 122 healthcare technology leaders from around the world (based on a comprehensive survey of 2,450 global technology leaders including chief digital officers, CIOs, CTOs, CISOs, chief AI officers and other executives) the report provides valuable insights into how healthcare systems and organizations are on the precipice of a technology revolution, and are leveraging advanced technologies and tools to streamline operations, reduce costs and, above all, enhance patient experiences.

“Today healthcare technology leaders believe robust regulatory frameworks are a must to ensure the safety and privacy of data in cloud-hosted solutions. They believe this assurance enables them to advance technological innovation with confidence. Prioritizing comprehensive data interoperability frameworks is critical for seamless communication between systems across organizations and jurisdictions. Such connectivity can drive accurate patient care, promote global collaboration in medical research, and strengthen AI model training through access to diverse datasets.” said Lalit Mistry Partner and Co-head, Healthcare Sector, KPMG in India.

Key Findings from the Report:

• 70 per cent of healthcare respondents are satisfied with the amount of value they are getting from their technology investments.
• Compared with a year ago, more healthcare organizations are developing and testing data and analytics strategies or already have a strategic vision for their capabilities
• 70 per cent say cyber security teams are typically involved in the earliest planning stages and have a high degree of influence when it comes to tech investment decision-making
• 66 per cent of healthcare technology leaders say their organizations are generating business value from several AI use cases
• 61 per cent of healthcare technology leaders are currently prioritising AI and Automation as they consider how to invest in technology to support their ambitions.
• 57 per cent admit that flaws in their organizations’ enterprise IT systems disrupt business as usual on a weekly basis.
• Top 3 factors slowing down digital transformation in healthcare includes – Cyber security and privacy concerns, transformation fatigue and immature data management strategies. 
• Healthcare leads all other sectors when it comes to prioritizing and investing in Web3 technology including blockchain and tokenization.

Indian Ophthalmologist Performs Asia’s First AI-Designed Intraocular Lens Implantation

Dr. Sri Ganesh, Founder and CMD of Nethradhama, became the first surgeon in Asia to carry out the procedure, which helps cataract and astigmatism patients achieve clear vision across all distances with reduced dependence on glasses.

Nethradhama Super Speciality Eye Hospital, Bengaluru, a pioneering institution in eye care, has performed Asia’s first AI-designed intraocular lens implantation. Under the leadership of Professor Dr. Sri Ganesh, Chairman & Managing Director of Nethradhama Super Speciality Eye Hospital and Founder Trustee of Shraddha Eye Care Trust, the hospital achieved this milestone, making him the first surgeon in Asia to carry out the procedure using Rayner RayOne Galaxy and Galaxy Toric intraocular lenses (IOLs).

“Our goal is always to provide the best solutions for our patients, and this innovation allows us to offer superior vision outcomes with minimal side effects,” said Dr. Sri Ganesh. “By leveraging AI-driven technology in intraocular lens design, we can achieve greater precision, enhanced customization, and improved patient satisfaction.”

This represents a notable advancement in AI-driven vision correction and a significant step forward in refractive cataract surgery, bringing us closer to more personalized vision solutions.

“The biggest challenge with previous IOLs has been balancing vision quality with night vision clarity,” explained Dr. Sri Ganesh. “This new lens overcomes this by using AI to optimize light distribution, giving patients an exceptional visual experience. It revolutionizes vision with its non-diffractive, AI-optimized spiral design, ensuring seamless clarity at all distances while enhancing contrast sensitivity. Unlike traditional trifocal lenses, it evenly distributes light across all focal points, reducing halos and glare for improved night vision. Its innovative optical structure enhances contrast even in low light, and the toric variant offers optimal rotational stability for precise astigmatic correction."

Dr. Sri Ganesh 

These lenses are specifically designed for patients with cataracts and astigmatism who seek reduced dependence—or complete independence—from glasses.

“For our patients, achieving true spectacle independence has always been a priority. They are particularly beneficial for individuals who require excellent vision across all distances while maintaining good night vision for driving and other low-light activities,” noted Dr. Sri Ganesh.

According to Dr. Sri Ganesh, the initial post-operative results have been extremely promising, with patients reporting excellent visual clarity within the first 24 hours. He added that long-term studies will continue to assess patient-reported experiences, particularly in real-world conditions like night driving and low-light environments.

Dr. Sri Ganesh is widely recognized for his expertise in high-risk surgeries, earning a stellar reputation in the field of advanced eye care. With an impeccable track record, he has performed over 100,000 Phaco surgeries and 50,000 Refractive surgeries, demonstrating exceptional surgical precision and innovation. His expertise is highly sought after on the global stage, serving on the advisory boards of leading companies such as Carl Zeiss Meditec Germany and J&J Vision USA. Beyond surgery, he has played a pivotal role in ophthalmic innovation, holding multiple patents for groundbreaking solutions that continue to shape the future of eye care.

To ensure an informed decision-making process, Nethradhama Super Speciality Eye Hospital offers comprehensive counseling and visual simulation sessions for patients considering these AI-designed IOLs. These sessions allow patients to preview their expected vision outcomes, including night vision improvements.

“With AI-driven advancements like these, we are witnessing a paradigm shift in ophthalmology. Our mission at Nethradhama Super Speciality Eye Hospital is to continually push the boundaries of innovation to provide our patients with the best possible visual outcomes. We are thrilled to bring this revolutionary technology to Asia and look forward to its impact on the future of vision correction,” added Dr. Sri Ganesh

Under Dr. Sri Ganesh’s leadership, Nethradhama is committed to innovation and excellence, continuously integrating state-of-the-art technologies to ensure the best possible visual outcomes for patients. Through its dedication to research, training, and compassionate care, it has established itself as a trusted name in eye health, both in India and globally.

Zoho's Sridhar Vembu To Co-Chair Oversee Committee for 3 AI CoEs

Dharmendra Pradhan to Announce 3 AI-CoE on Healthcare, Agriculture and Sustainable Cities on 15 Oct.'24

Union Minister for Education, Shri Dharmendra Pradhan, will be announcing three AI Centres of Excellence (CoE) focused on Healthcare, Agriculture, and Sustainable Cities on 15th October 2024 in New Delhi.

To realize the vision of "Viksit Bharat," these three CoEs for Artificial Intelligence (AI) will be led by top educational institutions, in consortium with industry partners and startups. They will conduct interdisciplinary research, develop cutting-edge applications, and create scalable solutions in these three areas. This initiative aims to galvanize an effective AI ecosystem and nurture quality human resources in these critical fields.

To oversee the implementation of this initiative, an industry heavy Apex Committee has been constituted, co-chaired by Dr. Sridhar Vembu, Founder and CEO of Zoho Corporation.

As part of the vision to "Make AI in India and Make AI work for India," the establishment of these centres was announced under Para 60 of the Budget Announcement for 2023-24. In alignment with this, the Government has approved the creation of the three AI Centres of Excellence, with a total financial outlay of Rs. 990.00 Cr over the period of FY 2023-24 to FY 2027-28.

Shri K.Sanjay Murthy, Secretary/HE will grace the occasion, along with Directors of IITs, Heads of higher educational institutions (HEIs), industry leaders, start-up founders and senior officials from various ministries of the Government of India.

Wipro Collab with IISc's Centre for Brain Research for AI/ML -powered R&D on Health and Wellbeing

Wipro Limited has announced a collaboration with the Centre for Brain Research (CBR) at the Indian Institute of Science (IISc) to pioneer AI-driven health behavior innovations. This partnership aims to leverage artificial intelligence (AI), machine learning (ML), and big data analytics to develop new technologies for precision support in the prevention and management of long-term health disorders.

The R&D team at Wipro, part of Lab45, will design and develop a personal care engine. This AI system will consider an individual's health history, desired health state, and other behavioral responses to promote healthy aging, positive lifestyle changes, and psycho-social wellbeing. The focus is on reducing and managing the risk of cardiovascular disease and correlated neurodegenerative disorders by personalizing interaction with users, optimizing for their long-term health and wellbeing.

Wipro will conduct a digital app-based trial in collaboration with CBR at IISc to test the engine's effectiveness for contexts deeply relevant for long-term health outcomes. The technological expertise of Wipro combined with the leading brain science research at CBR is expected to unlock new possibilities for patient care and cognitive and overall health. The joint R&D efforts will aim to develop systems that deliver better health outcomes at a population scale.

The personal care engine developed by Wipro in collaboration with the Centre for Brain Research at IISc is an AI-driven system designed to promote long-term health and psycho-social wellbeing. Below is how it works:

• Data Integration: The engine integrates various data points, including an individual's health history, behavioral responses, and their desired health state.
• AI and ML Algorithms: Using advanced AI and ML algorithms, the engine analyzes this data to identify patterns and make predictions.
• Personalization: It then personalizes its interaction with users, tailoring recommendations and support to encourage healthy aging and positive lifestyle changes.
• Health Management: The focus is on reducing the risk of cardiovascular disease and related neurodegenerative disorders by optimizing for the user's long-term health and wellbeing.
• App-Based Trial: Wipro will conduct a digital app-based trial to assess the engine's effectiveness in real-world scenarios, ensuring that the technology is beneficial for long-term health outcomes.

This personal care engine represents a significant step towards precision health, leveraging technology to deliver individualized care and support for managing chronic health conditions.

Dr. Ajay Chander, Head of Research and Development, Wipro Limited, said, “Our collaboration with CBR will pioneer solutions at the intersection of computing and cognitive sciences, bringing scalable personalized care support for some of the most chronic health challenges globally. Cardiovascular conditions are a particular focus for us, because of their strong association with long-term cognitive issues and the potential for broad health and wellbeing benefits at lower costs.”

Further emphasizing the importance of this partnership, Professor K.V.S. Hari, Director, Centre for Brain Research, said, “Working with Wipro allows us to amplify our scientific expertise through large-scale digital applications. This partnership will accelerate the path from research to real-world solutions in cognitive and overall health.”

Accenture Invests in Turbine, That is Building a Platform for Interpreting Human Biology Using AI

Accenture has made a strategic investment through Accenture Ventures in Turbine, a company that specializes in predictive simulation. This investment is aimed at accelerating the use of AI-powered cell simulations in biopharma research and development.

Turbine's core technology, the Simulated Cell™ platform, leverages machine learning to model molecular interactions within and around cells. This allows for virtual experiments that can reveal mechanisms driving diseases and responses to therapies. The platform is designed to perform virtual experiments at a scale nearly impossible in the physical world, thus providing valuable insights into biological systems.

This collaboration through the investment is expected to help global biopharma companies uncover hidden biological insights, which could guide and accelerate key drug development workstreams. It's particularly focused on uncovering promising drug targets, selecting patient populations most likely to benefit from therapy, and identifying combination therapy regimens.

The investment reflects Accenture's commitment to supporting technology and digital capabilities that drive innovation in AI-based drug discovery, with the ultimate goal of enhancing patient care and providing more effective treatments.

Turbine is the latest company to join Accenture Ventures’ Project Spotlight, an engagement and investment program focused on working with companies that create or apply disruptive enterprise technologies. Project Spotlight offers extensive access to Accenture’s domain expertise and its enterprise clients, helping startups harness creativity and deliver on the promise of their technology.

Earlier in March this year, Accenture, through Accenture Ventures, had invested in Sanctuary AI, a company specializing in the development of AI-powered humanoid robots.

Besides Turbine, other digital simulation companies in Project Spotlight include QuantHealth, Virtonomy and Ocean Genomics.

“Since most unsolved complex diseases are heterogenous, progress in utilizing AI for drug discovery is hindered by ethical and technological limitations in sourcing deep and diverse ground truth data. To bridge this gap, we need a toolkit that can learn fundamental rules of biology on in vitro experiments and apply to patients that it has never seen before. Turbine's Simulated Cells can be engineered at scale to represent the heterogeneity of complex human disease better than currently available wet lab experimental models, which are inherently biased towards representing certain disease types and hardly scalable,” said Szabolcs Nagy, co-founder and CEO of Turbine.

“By tapping into Accenture’s expertise, we hope to expand our market reach and augment our simulation platform in order to benefit the whole biopharma industry by ensuring that the next experiment is always the correct one", Nagy added.

Founded in 2015 by Kristof Szalay, Ph.D., Daniel Veres, M.D., Ph.D., Szabolcs Nagy and Ivan Fekete, M.D., Turbine is based in London, UK, with offices in Budapest, Hungary and Cambridge, UK. The team’s vision is to overcome the current limitations in identifying oncology treatments with true patient benefit by combining molecular biology and interpretable machine learning.

Turbine’s latest investment round (Series A) was closed in June 2023 which was €5.5 million from MassMutual Ventures. Prior to this, in 2022, Turbine raised finding which was co-led by MSD (Merck & Co., Inc., Rahway NJ, USA) Global Health Innovation Fund (GHIF) and Mercia Asset Management, who were joined by both new and existing investors Delin Ventures, Day One Capital, Accel, Atlantic Labs, XTX Ventures, o2h Ventures and Boston Millenia Partners.

Future Medicines To Be Completely Designed by AI

Generative Al will be designing new drugs all on its own in the near future

Generative AI is making significant strides in the field of drug discovery. It's being used to design new drugs by analyzing vast datasets and generating novel molecular structures that could potentially be strong drug candidates. For instance, scientists at pharmaceutical giant, Eli Lilly, have been surprised by the unique molecules that AI
has produced, which could not have been envisioned by human researchers.

Citing executives working at the industry of Al & healthcare cross-over, a CNBC report said that the AI-powered healthcare field is on a path that will see medicines completely generated by Artificial Intelligence (AI) in the near future.

Moreover, AI is expected to not only conceive new drugs but also create ones that humans might not be able to, thus expanding the horizons of medical science. The technology is advancing rapidly, and experts believe that within a few years, it will become a norm in drug discovery. This could significantly reduce the time and cost associated with developing new medications, leading to faster and more efficient healthcare solutions.

According to some, within a few years at most it will become a norm in drug discovery. Experts at Eli Lilly and NVIDIA say that within a few years, Al will not only think up new drugs, but ones that humans could not create.

Generative Al is rapidly accelerating its applicability to the developments and discovery of new medications, in a move that will reshape not only the pharmaceutical industry but ground-level ideas that have been built into the scientific method for centuries.

AlphaFold

A major precedent for AI-generated breakthroughs in biology was set in 2021 when Google’s DeepMind AI, came up with a novel protein called AlphaFold.

Google DeepMind and EMBL-EBI (European Bioinformatics Institute) have partnered to create the AlphaFold Protein Structure Database. This database provides open access to over 200 million protein structure predictions generated by AlphaFold.

Exscientia

Exscientia is a leading pharmatech company that uses Al to design and optimize molecular properties of drugs for patients, revolutionizing drug discovery. Exscientia combines advanced Al design with exacting experimental validation to rapidly progress a pipeline of drug discovery assets. The pharmatech company is spearheading the drug discovery revolution by creating the first Al-designed molecules to reach clinical trials.

Similarly, Insilico Medicine, a company with headquarters in Hong Kong and New York, has used AI to develop an experimental drug for idiopathic pulmonary fibrosis, an incurable lung disease. The treatment is in mid-stage trials in the US and China with some results expected early 2025.

However, the success of any AI-designed drugs will ultimately be tested by the traditional final step in drug development —performance in human trials.

Microsoft and Healthcare Leaders Create AI Network 'TRAIN' to Make AI in Health Safe and Trustworthy

New consortium of healthcare leaders announces formation of Trustworthy & Responsible AI Network (TRAIN), making safe and fair AI accessible to every healthcare organization

With start of this week, the HIMSS 2024 Global Health Conference has begin and a new consortium of healthcare leaders  announced the creation of the Trustworthy & Responsible AI Network (TRAIN), which aims to operationalize responsible AI principles to improve the quality, safety and trustworthiness of AI in health.

The Trustworthy & Responsible AI Network (TRAIN) is one of the first health AI networks aimed at operationalizing responsible AI principles.

Members of the network include AdventHealth, Advocate Health, Boston Children’s Hospital, Cleveland Clinic, Duke Health, Johns Hopkins Medicine, Mass General Brigham, MedStar Health, Mercy, Mount Sinai Health System, Northwestern Medicine, Providence, Sharp HealthCare, University of Texas Southwestern Medical Center, University of Wisconsin School of Medicine and Public Health, Vanderbilt University Medical Center, and Microsoft as the technology enabling partner.

Through collaboration, TRAIN members will help improve the quality, safety, and trustworthiness of AI in health by sharing best practices, enabling registration of AI used for clinical care or clinical operations, providing tools to enable measurement of outcomes associated with the implementation of AI, and facilitating the development of a federated national AI outcomes registry for organizations to share amongst themselves.

Additionally, the network is collaborating with OCHIN, which serves a national network of community health organizations with solutions, expertise, clinical insights and tailored technologies, and TruBridge, a partner and conduit to community healthcare, to help ensure that every organization, regardless of resources, has access to TRAIN’s benefits.

New AI capabilities have the potential to transform the healthcare industry by enabling better care outcomes, improving efficiency and productivity, and reducing costs. From helping screen patients, to developing new treatments and drugs, to automating administrative tasks and enhancing public health, AI is creating new possibilities and opportunities for healthcare organizations and practitioners. As new uses of AI in healthcare continue to unfold and grow, the need for rigorous development and evaluation standards becomes even more important to ensure effective and responsible applications of AI.

Through collaboration, TRAIN members will help improve the quality and trustworthiness of AI by:

Sharing best practices related to the use of AI in healthcare settings, including the safety, reliability and monitoring of AI algorithms, and the skillsets required to manage AI responsibly. Data and AI algorithms will not be shared between member organizations or with third parties.

Enabling registration of AI used for clinical care or clinical operations through a secure online portal.

Providing tools to enable measurement of outcomes associated with the implementation of AI, including best practices for studying the efficacy and value of AI methods in healthcare settings and leveraging of privacy-preserving environments, with considerations in both pre- and post-deployment settings. Tools that allow analyses to be performed in subpopulations to assess bias will also be provided.

Facilitating the development of a federated national AI outcomes registry for organizations to share among themselves. The registry will capture real-world outcomes related to efficacy, safety and optimization of AI algorithms.

For more information on the collaboration and to hear from founding members, join us at our session at HIMSS on Tuesday, March 12, 2024, from 3 to 4 p.m. ET, “Operationalizing Responsible AI in Healthcare: Challenges and Opportunities.”

“When it comes to AI’s tremendous capabilities, there is no doubt the technology has the potential to transform healthcare. However, the processes for implementing the technology responsibly are just as vital,” said Dr. David Rhew, global chief medical officer and vice president of healthcare, Microsoft. “By working together, TRAIN members aim to establish best practices for operationalizing responsible AI, helping improve patient outcomes and safety while fostering trust in healthcare AI.”

“At Advocate Health, innovation is at the core of our drive to advance the science of medicine,” said Dr. Rasu Shrestha, executive vice president and chief innovation and commercialization officer for Advocate Health. “As we seek to make care more accessible and affordable for all, address the root causes of health inequities and provide the best health outcomes for our patients, we believe the responsible application of AI and leveraging key partnerships in this space will be essential as we reimagine how care delivery can be improved in the future.”

"OCHIN is proud to join this strategic collaboration to help fuel the future of safe and inclusive healthcare innovation,” said Kim Klupenger, chief experience officer, OCHIN. “By participating in the operationalization of responsible AI principles, we’ll help ensure the diverse experiences of patients and providers from underserved communities are represented in the creation and adoption of new solutions that can drive efficiency and make day-to-day care delivery easier and more accessible across our growing network.”

Dr. Nigam Shah, chief data scientist, Stanford Healthcare, said, "As a co-founder and board member of the Coalition for Health AI (CHAI), I am excited to see health systems coming together to operationalize CHAI’s principles for Responsible and Trustworthy AI."

Remote Hilly-Areas or Udhampur, J&K Gets AI-backed Telemedicine Mobile Clinic

A state-of-the-art, Artificial Intelligence (AI) supported Telemedicine Mobile Clinic "Aarogya-Doctors on Wheels" for remote hilly areas of Ramnagar region in Udhampur district of J&K has been launched, this Sunday, by Union Minister Dr Jitendra Singh.

The latest upgraded Tele Clinic is Artificial Intelligence-driven to provide healthcare facilities in far flung areas of the region, where such facilities are either not available or inadequately available.

The mobile clinic functions on the latest methodology wherein a patient can narrate his illness or complaint in his native language and the AI doctor understands the language and responds to the patient in the same language.

Thereafter, the patient is connected to one of the leading super specialists in the country as this telemedicine hospital has been tied up with some of the leading hospitals in the country. Later, the patient's entire body profile and investigations are done. Within about 40 to 50 minutes, a patient is provided with the prescription. Dr Singh said the patient is provided free-of-cost treatment.

Dr Jitendra Singh said that Prime Minister Shri Narendra Modi has made a firm resolve to provide healthcare facilities to the remotest parts of the country, harnessing the latest technological developments. The present initiative is also inspired by that, he said.

The Minister informed that the first phase of this facility was conducted in the far-flung Gandoh area of district Doda where it spent three months. The second phase was conducted along the Zero Line villages of the International Border, and the third phase was held in the upper reaches of Bilawar. The fourth phase in the next few months will be conducted in Dudu Basantgarh in the upper reaches of Ramnagar block of Udhampur.

Dr Jitendra Singh appealed to local people to avail the facility, saying that through this latest super speciality hospital, doctors are coming to their doorsteps.

"This campaign, through funds raised from voluntary sources, was started in Udhampur Lok Sabha constituency one year back and it is possibly among the rare parliamentary constituencies to have initiative such a high tech mobile healthcare facility. For local assistance, a physician is also physically available inside the van, " said Dr Jitendra Singh. 

Wipro To Bring Generative AI To Healthcare Insurance Companies Using NVIDIA AI Enterprise

Collaboration brings together companies’ deep expertise and research in AI and large language models, powered by NVIDIA AI Enterprise software

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, has recently announced a collaboration with NVIDIA to help healthcare companies accelerate adoption of generative artificial intelligence (gen AI) through AI-driven strategies, products, and services.

Wipro will leverage NVIDIA AI Enterprise software for the production of AI across its current portfolio of healthcare solutions in Affordable Care Act (ACA), Medicare, and Medicaid to improve member experience, increase enrolment, and help support claims adjudication. As a result, healthcare organizations will be able to achieve faster, and easier consumption of large language models (LLMs) powered by NVIDIA AI Enterprise, leading to increased productivity, deeper member intelligence, and better operational efficiencies and paving the way for the next wave of healthcare solutions.

“We are delighted to team with NVIDIA to develop next-generation, scalable AI solutions to help our healthcare clients tap into the power of generative AI,” said Nagendra Bandaru, President and Managing Partner, Wipro Enterprise Futuring. “This collaboration will allow us to deliver AI-enabled innovation for the healthcare industry at scale and drive healthcare solutions with advanced computing capabilities. We are looking forward to building healthcare specific solutions for a new era of AI-led innovation and business transformation.”

The collaboration will leverage the NVIDIA AI platform for generative, speech, and translation AI, including NVIDIA AI Foundation Models for building and customizing generative AI models for any application in the NVIDIA AI Enterprise software, such as NVIDIA NeMo and Riva, and the NVIDIA DGX platform.

The integration of these technologies with Wipro’s Enterprise Generative AI (WeGA) framework will enable Wipro to co-develop and deploy custom models for speech and translation AI, as well as other LLMs. Wipro has already developed multiple AI-first enterprise offerings across the healthcare industry leveraging the NVIDIA AI platform. These include an industry-leading billing and enrolment solution in the Medicare and ACA market segment, provider and member services leveraging gen AI capabilities, and specific offerings to improve claims processing and provider data accuracy.

“We are excited to expand on this collaboration with NVIDIA. Wipro’s deep healthcare experience, innovative AI frameworks, and platforms combined with NVIDIA’s leadership in accelerated computing and AI will help the world’s largest healthcare entities to embrace new AI capabilities and re-imagine their business,” said Jason Eichenholz, Senior Vice President and Global Head of Ecosystems & Partnerships at Wipro.

Wipro plans to continue building NVIDIA-powered solutions that will help automate the software development lifecycle and accelerate digital and business transformation. Through an AI Center of Excellence with NVIDIA, Wipro engineers will receive large-scale ongoing training on NVIDIA’s application frameworks in areas like generative AI, the metaverse, conversational AI, and data analytics to accelerate the development of custom solutions.

“Companies are eager to integrate multilingual, voice-enabled generative AI into business applications that are powered by the highest-performing, most energy-efficient solutions available,” said Manuvir Das, Vice President of Enterprise Computing at NVIDIA. “The NVIDIA AI platform supports Wipro’s ongoing commitment to provide its clients with the most advanced, secure, and reliable AI technology and services.”

Most recently, Wipro has been working with the healthcare sector in transforming the contact center experience through generative, speech, and translation AI, providing patients with accurate, contextual, personalized, and timely responses to their care needs based on their past medical records, claim history, and provider information.

For more information on Wipro’s collaboration with NVIDIA, please visit https://www.wipro.com/partner-ecosystem/nvidia-alliance/

About Wipro Limited

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading technology services and consulting company focused on building innovative solutions that address clients’ most complex digital transformation needs. Leveraging our holistic portfolio of capabilities in consulting, design, engineering, and operations, we help clients realize their boldest ambitions and build future-ready, sustainable businesses. With 250,000 employees and business partners across more than 60 countries, we deliver on the promise of helping our clients, colleagues, and communities thrive in an ever-changing world. For additional information, visit us at www.wipro.com.

Biotech Firm Eyestem Partners with RetinAI to Innovate Geographic Atrophy Clinical Research Using State-of-the-Art AI Technology

Eyestem Research, a Bangalore-based biotechnology company specialising in cell therapy approaches, has entered a strategic partnership with Ikerian AG and RetinAI Inc. US (“RetinAI”), a pioneer in clinical and imaging data management software and advanced AI-driven analytics for ophthalmology.

Leveraging RetinAI’s Discovery® platform and AI tools will enable Eyestem to advance in its mission to revolutionise treatment for geographic atrophy with its innovative cell therapy, Eyecyte-RPE™.

“This collaboration with RetinAI marks a significant milestone in our journey,” said Dr Jogin Desai, Founder and CEO of Eyestem. “Their sophisticated AI tools and the RetinAI Discovery® platform integrate perfectly with our vision, potentially shortening the timelines for our clinical trials and enhancing the accuracy of our analyses. This is not just a partnership; it’s a confluence of high-end biotech innovation and cutting-edge artificial intelligence aiming to rewrite the narrative for patients affected by geographic atrophy worldwide.”

Dr. Carlos Ciller, CEO of RetinAI, expressed his enthusiasm about the collaboration: “We are excited to partner with Eyestem, known for its forward-thinking approach to biotechnology and cell therapy. Our AI-driven Discovery® platform is poised to significantly accelerate research and provide enhanced insights into disease progression and outcomes. Together, we’re confident that this synergy will not only enrich insights in the development of novel treatments but also manifest in delivering life-altering solutions faster to individuals affected by retinal diseases globally.”

Geographic atrophy, a late-stage form of dry age-related macular degeneration (AMD), is a significant health concern worldwide. Currently, dry AMD affects 200 million individuals globally, contributing to irreversible vision loss. Compounded by an aging population, the prevalence of this serious eye disease is escalating at an alarming rate.

Eyestem is taking a significant step forward by preparing to initiate its Phase I/IIa clinical trials for Eyecyte-RPE™. This multi-centre, dose escalation, and expansion trial aims to assess Eyecyte-RPE™’s safety and efficacy for geographic atrophy. This trial will benefit from RetinAI’s Discovery® platform, which will centralise data management and image analysis for the study. Moreover, RetinAI’s advanced segmentation model will be leveraged for the identification and quantification of retinal biomarkers in geographic atrophy. This automated analysis will provide real-time insights on clinical endpoints, speeding up critical decision-making.

About RetinAI

Established in 2017, Ikerian AG (formerly RetinAI Medical AG) and its subsidiary, RetinAI US Inc., are transforming clinical and pharmaceutical research with cutting-edge machine learning and computer vision. Their collaboration with healthcare experts enhances data analysis for improved research and clinical trials. RetinAI's platform's extensive list of AI models, including for major ophthalmic disorders like Geographic Atrophy, enable detailed analysis of large datasets, offering critical insights into patient demographics and biomarker profiles. This innovation not only expedites informed decision-making but also shifts the healthcare paradigm from reactive to proactive. Discover more of the solutions for pharma here: https://www.retinai.com/solutions/life-sciences-pharma and on their website: www.retinai.com.

About Eyestem

Based in Bangalore and Delaware, Eyestem Research is a clinical-stage biotech company founded by an experienced team in pharmaceuticals, ophthalmology, and cell biology. It's recognised as a top innovator nationwide, earning accolades from Economic Times in 2022. Eyestem has received grants from the Indian Department of Biotechnology and has been celebrated as a successful startup at government events. Backed by global investors, including Switzerland and South Africa, it's supported by prestigious venture capital firms Kotak Investment Advisors and Endiya Partners. Its recent funding came from three major Indian pharmaceutical companies: Alkem Laboratories, NATCO, and Biological E.

In A World’s 1st in Drug Discovery, AI Develops A Treatment for Cancer in 30 Days

Researchers at the University of Toronto have developed a potential treatment for liver cancer using artificial intelligence

The team applied AlphaFold, an Al-powered protein structure database, to uncover a novel treatment pathway for cancer. The creation of the potential drug was accomplished in just 30 days, and the Al system can also predict a patient's survival rate.

According to the study published in the journal Chemical Science, researchers at the University of Toronto along with Insilico Medicine developed a potential treatment for hepatocellular carcinoma (HCC) — the most common type of primary liver cancer — with an AI drug discovery platform called Pharma.AI, an end-to-end AI-powered drug discovery platform.

The study is being touted as the world’s first to apply a groundbreaking AI technology, AlphaFold, to drug discovery research.

The researchers included a biocomputational engine, PandaOmics, and a generative chemistry engine, Chemistry42. They discovered a novel target for HCC – a previously undiscovered treatment pathway – and developed a “novel hit molecule” that could bind to that target without the aid of an experimentally determined structure.

The scientists first used AI to scan HCC for protein “weak spots.” Once one was detected, another program designed small molecules that could target and take down the specific protein, the paper says. Researchers then tested these molecules on live cells, one of which appeared effective at slowing cancer growth.

This feat was accomplished in just 30 days from target selection and after only synthesizing seven compounds.

“This paper is further evidence of the capacity for AI to transform the drug discovery process with enhanced speed, efficiency, and accuracy,” Michael Levitt, a Nobel Prize winner in chemistry, said. “Bringing together the predictive power of AlphaFold and the target and drug-design power of Insilico Medicine’s Pharma.AI platform, it’s possible to imagine that we’re on the cusp of a new era of AI-powered drug discovery.”

In a statement, Alex Zhavoronkov, founder and CEO of Insilico medicine, said, "While the world was fascinated with advances in generative AI in art and language, our generative AI algorithms managed to design potent inhibitors of a target with an AlphaFold-derived structure."

Insilico Medicine is a biotechnology company based in Hong Kong and New York.

AlphaFold is an artificial intelligence program developed by DeepMind, a subsidiary of Alphabet, the parent company of Google.

Last year, AlphaFold predicted protein structures for the whole human genome – a remarkable breakthrough in both AI applications and structural biology.